Skip to main content

Table 1 Eligible/noneligible patients at prescreening and numbers screened and enrolled for the five core sites

From: Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience

Study site Total pool Noneligible Eligible Screened Enrolled
n
(% of total pool)
Mean age (years) Male, n
(% of noneligible)
Female, n (% of noneligible) n
(% of total pool)
Mean age (years) Male, n (% of eligible) Female, n (% of eligible) n
(% of eligible)
n
(% of eligible)
Essen 109 24 (22.0) 71 7 (29.2) 17 (70.8) 85 (78.0)     5 (5.9) 2 (2.4)
Glostrup 221 160 (72.4) 67 54 (33.8) 106 (66.2) 61 (27.6) 64 29 (47.5) 32 (52.5) 12 (19.7) 6 (9.8)
London 161 82 (50.9) 67 29 (35.4) 53 (64.6) 79 (49.1) 60 30 (38.0) 49 (62.0) 1 (1.3) 0
Rome 130 46 (35.4) 69 14 (30.4) 32 (69.6) 84 (64.6) 63 28 (33.3) 56 (66.7) 28 (33.3) 15 (17.9)
Zurich 15 2 (11.1) 62 0 2 (100.0) 13 (88.9) 58 4 (30.8) 9 (69.2) 10 (62.5) 3 (18.8)
TOTAL 636 314 (49.1)     322 (50.6)     56 (17.4) 26 (8.1)